title: Host responses in human skin after conventional intradermal injection or microneedle administration of virus-like-particle influenza vaccine.
abstract: Miniaturized microneedle devices are being developed for painlessly targeting vaccines to the immune cell populations in skin. As skin immunization studies are generally restricted to animal models however, where skin architecture and immunity is greatly different to human, surprisingly little is known about the local human response to intradermal (ID) vaccines. Here surgically excised human skin is used to explore for the first time the complex molecular and cellular host responses to a candidate influenza vaccine comprising nanoparticulate virus-like-particles (VLPs), administered via conventional hypodermic injection or reduced scale microneedles. Responses at the molecular level are determined by microarray analysis (47,296 discrete transcripts) and validated by quantitative PCR (96 genes). Cellular response is probed through monitoring migration of dendritic cells in viable skin tissue. Gene expression mapping, ontological analysis, and qPCR reveal up-regulation of a host of genes responsible for key immunomodulatory processes and host viral response, including cell recruitment, activation, migration, and T cell interaction following both ID and microneedle injection of VLPs; the response from the microneedles being more subtle. Significant morphological and migratory changes to skin dendritic cells are also apparent following microneedle VLP delivery. This is the first study displaying the global, multifaceted immunological events that occur at the site of vaccine deposition in human skin and will subsequently influence the degree and nature of innate and adaptive immune responses. An increased understanding of the detailed similarities and differences in response against antigen administered via different delivery modalities will inform the development of improved vaccines and vaccine delivery systems.
authors.affiliation: School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Redwood Building, King Edward VII Avenue, Cardiff, CF10 3NB, UK.
authors.forename: Marc
authors.initials: M
authors.lastname: Pearton
authors.forename: Daniela
authors.initials: D
authors.lastname: Pirri
authors.forename: Sang-Moo
authors.initials: SM
authors.lastname: Kang
authors.forename: Richard W
authors.initials: RW
authors.lastname: Compans
authors.forename: James C
authors.initials: JC
authors.lastname: Birchall
mesh_terms: D002465:Cell Movement; D016000:Cluster Analysis; D005260:Female; D006801:Humans; D007113:Immunity, Innate; D007150:Immunohistochemistry; D066298:In Vitro Techniques; D007252:Influenza Vaccines / Q000008:administration & dosage* / Q000276:immunology; D007271:Injections, Intradermal; D007801:Langerhans Cells / Q000166:cytology; D008875:Middle Aged; D009339:Needles; D012867:Skin / Q000276:immunology / Q000378:metabolism* / Q000473:pathology; D013601:T-Lymphocytes / Q000276:immunology / Q000378:metabolism; D059467:Transcriptome; D058425:Vaccines, Virus-Like Particle / Q000008:administration & dosage* / Q000276:immunology
chemical_list: D007252:Influenza Vaccines; D058425:Vaccines, Virus-Like Particle
keywords: gene expression; human skin; influenza; intradermal; microneedle; virus-like-particles
references.citation: Sci Rep. 2012;2:357
references.pmid: 22500210
references.citation: J Virol. 2009 May;83(9):4489-97
references.pmid: 19211762
references.citation: Pharm Res. 2011 Jan;28(1):95-106
references.pmid: 20238152
references.citation: Pharm Res. 2006 Jan;23(1):104-13
references.pmid: 16308670
references.citation: Vaccine. 2012 Jan 11;30(3):523-38
references.pmid: 22100637
references.citation: PLoS One. 2010 Aug 25;5(8):e12410
references.pmid: 20811642
references.citation: Biomed Microdevices. 2009 Feb;11(1):35-47
references.pmid: 18663579
references.citation: Vaccine. 2012 Jun 13;30(28):4216-24
references.pmid: 22542815
references.citation: J Immunol. 2004 Aug 1;173(3):1951-8
references.pmid: 15265929
references.citation: PLoS One. 2010 Apr 21;5(4):e10266
references.pmid: 20422002
references.citation: BMC Infect Dis. 2010 May 26;10:134
references.pmid: 20504306
references.citation: Curr Top Microbiol Immunol. 2009;333:369-93
references.pmid: 19768415
references.citation: Proc Natl Acad Sci U S A. 1994 Sep 27;91(20):9519-23
references.pmid: 7937799
references.citation: Annu Rev Biochem. 1998;67:227-64
references.pmid: 9759489
references.citation: Sci Transl Med. 2012 Jan 18;4(117):117fs2
references.pmid: 22261029
references.citation: Nat Immunol. 2004 Oct;5(10):971-4
references.pmid: 15454919
references.citation: Med J Aust. 2007 Jul 2;187(1):58-9
references.pmid: 17605714
references.citation: Hum Vaccin Immunother. 2012 Jan;8(1):67-75
references.pmid: 22293531
references.citation: J Invest Dermatol. 2012 Mar;132(3 Pt 1):615-25
references.pmid: 22170490
references.citation: Annu Rev Immunol. 2004;22:891-928
references.pmid: 15032599
references.citation: J Immunol. 2004 Mar 1;172(5):2731-8
references.pmid: 14978070
references.citation: J Control Release. 2010 Nov 1;147(3):326-32
references.pmid: 20692307
references.citation: Lancet. 1983 Dec 24-31;2(8365-66):1454-6
references.pmid: 6140546
references.citation: Expert Rev Vaccines. 2012 May;11(5):547-60
references.pmid: 22697052
references.citation: Int J Pharm. 2001 Mar 14;215(1-2):51-6
references.pmid: 11250091
references.citation: J Diabetes Sci Technol. 2007 Sep;1(5):725-9
references.pmid: 19885141
references.citation: Vaccine. 2009 Oct 9;27(43):5948-55
references.pmid: 19679220
references.citation: Bull World Health Organ. 2011 Mar 1;89(3):221-6
references.pmid: 21379418
references.citation: Immunity. 2008 Dec 19;29(6):835-8
references.pmid: 19100694
references.citation: Clin Infect Dis. 1992 Mar;14(3):697-707
references.pmid: 1532914
references.citation: Hum Vaccin. 2010 Jul;6(7):562-5
references.pmid: 20523131
references.citation: Adv Drug Deliv Rev. 2012 Nov;64(14):1547-68
references.pmid: 22575858
references.citation: Hum Vaccin. 2008 May-Jun;4(3):246-50
references.pmid: 18382138
references.citation: Eur J Pharm Sci. 2012 May 12;46(1-2):1-7
references.pmid: 22330147
references.citation: Vaccine. 2011 Mar 21;29(14):2626-36
references.pmid: 21277407
references.citation: Expert Rev Med Devices. 2006 Jan;3(1):1-4
references.pmid: 16359245
references.citation: Curr Opin Immunol. 2007 Dec;19(6):652-7
references.pmid: 17766098
references.citation: Annu Rev Immunol. 2009;27:485-517
references.pmid: 19132915
references.citation: Hum Immunol. 2002 Dec;63(12):1164-71
references.pmid: 12480260
references.citation: Pharm Res. 2011 Jan;28(1):66-81
references.pmid: 20464461
references.citation: Pathol Biol (Paris). 2003 Mar;51(2):59-60
references.pmid: 12801800
references.citation: Virology. 2007 Jun 5;362(2):331-41
references.pmid: 17276476
references.citation: Vaccine. 2008 Jun 19;26(26):3197-208
references.pmid: 18486285
references.citation: Vaccine. 2010 Aug 16;28(36):5850-6
references.pmid: 20600481
references.citation: J Virol. 2011 Nov;85(21):11391-400
references.pmid: 21865389
references.citation: J Exp Med. 2009 Jul 6;206(7):1589-602
references.pmid: 19564349
references.citation: J Immunol. 2006 Dec 1;177(11):8008-16
references.pmid: 17114474
references.citation: J Pathol. 2003 Jan;199(1):98-106
references.pmid: 12474232
references.citation: Immunol Rev. 2011 Jan;239(1):8-26
references.pmid: 21198662
references.citation: Vaccine. 2010 Aug 23;28(37):6104-13
references.pmid: 20685601
references.citation: J Virol. 2006 Sep;80(18):9134-43
references.pmid: 16940524
references.citation: mBio. 2012 Mar 06;3(2):e00012-12
references.pmid: 22396479